Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Enteris BioPharma is looking to make some money on the side of its drug-delivery operation, opening a contract manufacturing facility and scouting for clients.
Catalent is investing in infrastructure again, spending to flesh out its European network of storage and packaging facilities in response to an increase in demand on the continent.
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.
Months removed from a $150 million IPO, INC Research is looking to raise its profile among the world's largest CROs, inching toward the $1 billion annual revenue mark in the new year.
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015.
Global CRO Quintiles is planning to lay off about 270 workers, 1% of its payroll, in an effort to reduce "excess capacity," the company said.
Acquisitive Chinese CRO WuXi PharmaTech is borrowing up to $165 million to keep up its string of deals, eyeing investments in R&D and manufacturing.
CRO giant Parexel International has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.
Theorem Clinical Research has signed a deal with Biomedical Systems to expands its testing services, enlisting a partner with expertise in diagnostics.
PRA Health Sciences, the latest CRO to go public, is expecting up to 10% revenue growth in 2015, hoping to top a transformational year that reshaped its business.